Skip to main content

Table 4 Risk of prostate cancer (PCa) death and biochemical recurrence (BCR), relative to previous grade grouping, by biopsy grade

From: Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings

Treatment sub-group

PCa deaths

 

BCRa

 
 

Adjusted sHR (95%CI)

p

Adjusted sHRb (95%CI)

p

Radical prostatectomy

 Grade group I (3 + 3)

-

 

-

-

 Grade group II (3 + 4)

1.6 (0.4–6.1)

0.48

2.0 (1.4–2.8)

<0.001

 Grade group III (4 + 3)

1.4 (0.3–6.5)

0.64

2.1 (1.5–2.8)

<0.001

 Grade group IV (8)

4.2 (1.0–17.1)

0.05

1.4 (0.9–2.0)

0.12

 Grade group V (9–10)

3.0 (0.8–10.9)

0.10

1.8 (1.0–3.1)

0.05

Curative radiotherapy

 Grade group I (3 + 3)

-

 

-

 

 Grade group II (3 + 4)

1.4 (0.7–3.0)

0.37

1.2 (0.7–1.8)

0.32

 Grade group III (4 + 3)

1.6 (0.9–3.1)

0.13

2.0 (1.3–3.1)

0.001

 Grade group IV (8)

0.9 (0.4–2.0)

0.74

0.8 (0.5–1.4)

0.41

 Grade group V (9–10)

1.4 (0.6–3.5)

0.46

1.3 (0.7–2.4)

0.46

Conservative managementc

 Grade group I (3 + 3)

-

   

 Grade group II (3 + 4)

3.0 (1.5–5.8)

0.001

Not applicable

 

 Grade group III (4 + 3)

0.7 (0.4–1.4)

0.35

-

 

 Grade group IV (8)

1.9 (1.0–3.4)

0.04

-

 

 Grade group V (9–10)

2.1 (1.3–3.4)

0.004

-

 
  1. aFor analysis of BCR, cases were excluded if <2 post- treatment PSA measures were recorded (273 (17%) cases excluded for prostatectomy group; 206 (18%) cases excluded for radiotherapy subgroup)
  2. bsHR: Subdistribution-hazard ratios derived from multivariable competing risk regression adjusted for age, year of diagnosis, diagnostic PSA, clinical stage, area level SES, and public/private management
  3. cThe conservative management group consists of men who were managed through watchful waiting, active surveillance or androgen deprivation therapy alone
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us